

Special Issue

Natural Compounds with Activity against Ovarian Cancer: In Memory of Michelle Kendall, an Ovarian Cancer Warrior (1973–2021)

Message from the Guest Editor

Ovarian cancer (OC) is the second most common and the most lethal gynecologic malignancy in the Western world. Late-stage ovarian cancer is incurable in the majority of cases. Most women have advanced disease, for which the standard of care remains as surgery and platinum-based cytotoxic chemotherapy. Additional treatments include targeted therapies that target specifically cancer-related processes necessary for tumor growth, division and spread. Nevertheless, in about 80% of cases, on average, disease relapse is expected after 24 months, and ultimately, multi-drug resistance develops, with very few women surviving five years after diagnosis. A large number of plant compounds have anti-cancer activity. Some plants (e.g., *Cannabis sativa*, *Moringa oleifera*, *Camellia sinensis*, *Pao pereira*, *Xylocarpus granatum*, *Margaritaria discoidea*, and *Rauwolfia vomitoria*) and molecules (e.g., phytocannabinoids, resveratrol, tetrandrine, naringin, and soy protein) were examined for their anti-OC activity in vivo, in vitro, and in clinical trials.

Guest Editor

Prof. Dr. Hinanit Koltai

Institute of Plant Sciences, Agriculture Research Organization, Volcani Institute, Rishon LeZion 7505101, Israel

Deadline for manuscript submissions

closed (1 March 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/126383

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).